DBV Technologies Appoints Kevin Trapp as Chief Commercial Officer
Paris, France – DBV Technologies, a clinical-stage biopharmaceutical company, has announced the immediate appointment of Kevin Trapp as chief Commercial Officer. Reporting to Managing Director Daniel Tasse, Trapp will lead the advancement and execution of the company’s commercial strategy for it’s Viaskin Peanut patch, a potential treatment for peanut allergies.
the appointment comes as DBV prepares for key milestones in the Viaskin Peanut program.The company anticipates submitting a Biologics License Application (BLA) to regulatory authorities in the first half of 2026 for children aged 4-7 years old, followed by a similar submission for children aged 1-3 years old in the second half of the year. These submissions will be supported by results from the ongoing Phase 3 VITESSE study, expected in the fourth quarter of this year, focusing on children aged 4-7.
Daniel Tassé highlighted Trapp’s prior involvement with DBV, stating, “Kevin has been a key contributor to DBV’s commercial strategy since 2017, both as an executive and a consultant. His leadership, strategic vision and deep understanding of our science and mission will be essential assets as we approach eventual commercialization.”
Trapp brings over 30 years of biopharmaceutical industry experience to the role. Most recently, he served as Managing Director at Biotech Value Advisors (BVA), advising biotechnology companies on commercial strategy and launch planning. Prior to BVA, he held a series of increasingly responsible positions at Bristol-Myers Squibb (BMS) spanning finance, sales, marketing, and general management. During his tenure at BMS, he oversaw a product portfolio valued at approximately $4 billion and contributed to the successful launch of over ten products and indications, including Abilify, Atripla, Reyataz, Orencia, and Daklinza.
“The mission of launching the viaskin Peanut Patch… truly matters in patients’ lives,” said Trapp. He expressed confidence in DBV’s regulatory progress and the potential of the Viaskin Peanut patch to offer a new treatment option for families affected by peanut allergies.
Trapp holds a degree from the University of connecticut School of Business and is a graduate of the general Management Program at CEDEP-INSEAD.
